Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED, savolitinib and surufatinib, will be presented at the ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized.

They also show that models learned from nonsynonymous mutations and from out-of-frame sequences are different, prompting new questions about germinal center function. Strengths of the study include an ...

The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

Frequent mutations of SARS-CoV-2 have reduced the effectiveness of vaccines, highlighting the need for mutation-resistant ...

The way they did it was to design a custom, synthetic cannabinoid molecule that is positively charged, which prevents it from being able to cross the blood-brain barrier. This means it can’t bind to ...

An international group of researchers has identified an important mechanism that enables stem cells to evade immune rejection ...